- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.02. | Cinclus Pharma Holding AB: Cinclus Pharma: FDA Determines That a Single Pivotal Study Is the New Standard for Market Approval in the US - Positive for the Company's Phase III Program | 173 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for acid-related gastrointestinal diseases, today announces that the FDA has clarified... ► Artikel lesen | |
| 18.02. | Cinclus Pharma Holding AB: Year-end report - Advancing toward Phase III readout | 131 | GlobeNewswire (Europe) | "The past year was marked by significant progress for Cinclus Pharma. Our first Phase III study has had a promising start, and we expect to present topline results during the second half of the year.... ► Artikel lesen | |
| 13.02. | Cinclus Pharma Holding AB: Cinclus Pharma receives positive assessment of its nonclinical development plan from the FDA | 129 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases, today announced that the US Food and Drug Administration... ► Artikel lesen | |
| 10.02. | Cinclus Pharma Holding AB: Cinclus Pharma receives regulatory support - EMA provides positive feedback on CMC for linaprazan glurate | 120 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases, today announced that the European Medicines Agency... ► Artikel lesen | |
| 19.01. | Cinclus Pharma Holding AB: Resolutions at the Extraordinary General Meeting in Cinclus Pharma Holding AB (publ) on 19 January 2026 | 387 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ) (Reg. No. 559136-8765) today, on 19 January 2026, held an Extraordinary General Meeting.The Extraordinary General Meeting resolved, in accordance with the Nomination... ► Artikel lesen | |
| 08.12.25 | Cinclus Pharma Holding AB: Cinclus Pharma recruits Magnus Christensen as new CFO | 263 | GlobeNewswire (Europe) | Cinclus Pharma today announces that Magnus Christensen has been recruited as CFO after Maria Engström, at her own request, has chosen to leave her role. He comes most recently from a role as CFO at... ► Artikel lesen | |
| CINCLUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 20.11.25 | Cinclus Pharma Q3 2025: Fortschritte in Phase-3-Studie bei anhaltend hohen F&E-Investitionen | 2 | Investing.com Deutsch | ||
| 20.11.25 | Cinclus Pharma Q3 2025 slides: Phase 3 trial progress amid continued R&D investment | 1 | Investing.com | ||
| 20.11.25 | Cinclus Pharma Holding AB: A positive start to the Phase III study | 186 | GlobeNewswire (Europe) | "Cinclus Pharma has now entered late-stage clinical development following the initiation of its first Phase III study, and patient recruitment has so far progressed well. Topline results are expected... ► Artikel lesen | |
| 07.10.25 | Cinclus Pharma Holding AB: Cinclus Pharma doses first patient in Phase III study evaluating linaprazan glurate for the treatment of erosive gastroesophageal reflux disease | 153 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing the next-generation treatments for acid-related diseases, today announced that the first patient has been dosed... ► Artikel lesen | |
| 12.09.25 | Cinclus Pharma Holding AB: Cinclus Pharma announces screening of first patient in HEEALING 1 Phase III trial evaluating linaprazan glurate for the treatment of erosive GERD | 252 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for acid-related diseases, today announced the screening of the first patient with... ► Artikel lesen | |
| 29.08.25 | Cinclus Pharma Holding AB: Cinclus Pharma to initiate HEEALING 1 Phase III study of linaprazan glurate in patients with Erosive Gastroesophageal Reflux Disease (GERD) | 493 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company developing the next generation of treatments for acid-related diseases, today announced the initiation of its Phase III HEEALING... ► Artikel lesen | |
| 20.08.25 | Cinclus Pharma Holding AB: Interim report January-June 2025 - Strengthened position for future value creation | 290 | GlobeNewswire (Europe) | "Our recently announced partnership with Zentiva k.s. for commercialization and manufacturing in Europe is a strong validation of both our product and strategic direction. This collaboration lays the... ► Artikel lesen | |
| 16.06.25 | Cinclus Pharma Holding AB: Cinclus Pharma secures EMA and FDA pediatric study waivers for linaprazan glurate in H. pylori infection | 254 | GlobeNewswire (Europe) | Cinclus Pharma AB (publ), a clinical-stage pharmaceutical company developing next generation treatments for acid-related diseases, today announced that the European Medicines Agency (EMA) and the US... ► Artikel lesen | |
| 20.05.25 | Cinclus Pharma Holding AB: Interim report January-March 2025 | 357 | GlobeNewswire (Europe) | "In parallel with the preparations for the Phase III study, we are strengthening our presence and visibility in academia and the medical profession and intensifying the work for an upcoming commercialization.... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CSPC PHARMA | 0,968 | -0,07 % | CSPC PHARMA (01093): PROPOSED AMENDMENTS TO THE EXISTING ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW ARTICLES OF ASSOCIATION | ||
| BACHEM | 74,90 | -1,06 % | Bachem FY25 Earnings Rise; Proposes Dividend Increase; Guides FY26 | WASHINGTON (dpa-AFX) - Bachem Holding AG (BCHMY, BCHMF), a Swiss biotechnology company, on Thursday reported higher full-year 2025 net income compared with the previous year, proposed a dividend... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 4,170 | -3,02 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 62,95 | -3,08 % | BridgeBio Pharma, Inc.: BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ||
| OPUS GENETICS | 4,480 | -1,75 % | Aktionäre von Opus Genetics billigen Direktorenwahl und Erhöhung des genehmigten Kapitals | ||
| ONO PHARMACEUTICAL | 12,175 | -1,77 % | Dividendenbekanntmachungen (30.03.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 77 BANK LTD JP3352000008 113 JPY 0,6124 EUR ACOM CO LTD JP3108600002 10 JPY 0,0542 EUR ADAMAS TRUST INC US6496048405 0,23 USD 0... ► Artikel lesen | |
| ELEDON PHARMACEUTICALS | 3,440 | +1,78 % | Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results | Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase... ► Artikel lesen | |
| CIPHER PHARMACEUTICALS | 11,700 | 0,00 % | Cipher Pharmaceuticals übertrifft Gewinnerwartungen, verfehlt aber Umsatzziel | ||
| BAYER | 40,240 | +0,52 % | Ihre wichtigsten Termine: Alle Blicke auf: Bayer, Deutsche Telekom, Hewlett Packard Enterprise & Clariant | © Foto: Bernd von Jutrczenka - dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine... ► Artikel lesen | |
| MERCK KGAA | 115,60 | -1,62 % | ANALYSE-FLASH: Goldman senkt Ziel für Merck KGaA auf 147 Euro - 'Buy' | NEW YORK (dpa-AFX Broker) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Merck KGaA von 153 auf 147 Euro gesenkt, aber die Einstufung auf "Buy" belassen. Analyst James Quigley rechnet mit... ► Artikel lesen | |
| NOVO NORDISK | 33,355 | -0,68 % | Aktien unter Druck, aber mit deutlichem Potenzial - dynaCERT Inc., Eli Lilly, K+S, Novo Nordisk | Am Wochenende scheiterten die Verhandlungen zur Beendigung des Krieges zwischen den USA und dem Iran, doch schon Ende dieser Woche soll es bereits eine nächste Verhandlungsrunde geben. Das machte sich... ► Artikel lesen | |
| PFIZER | 22,900 | -1,67 % | Astellas, Pfizer Say FDA Grants Priority Review To SBLA For PADCEV Plus Keytruda | TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY) and Pfizer Inc. (PFE) on Monday said the U.S. Food and Drug Administration has granted Priority Review for a supplemental Biologics License Application... ► Artikel lesen | |
| SANOFI | 80,80 | -0,22 % | Entschlüsselung fehlregulierter Immunreaktionen: Forschung bei Sanofi an neuen Therapieoptionen für Autoimmunerkrankungen | Frankfurt/Main (ots) - Autoimmunerkrankungen betreffen weltweit Millionen von Patient*innen. Sie erfordern oft lebenslange Behandlung. Trotz bedeutender medizinischer Fortschritte sprechen nicht alle... ► Artikel lesen | |
| ELI LILLY | 783,80 | +1,77 % | Is Eli Lilly Stock Actually ... Cheap? The Surprising Math Behind Its 2026 Valuation. | ||
| CANOPY GROWTH | 1,184 | +22,29 % | Nach den Tilray-Zahlen: Aurora, Canopy & Co. vor richtungsweisender Berichtssaison | In einer Phase, in der sich das Handelsgeschehen auf die Auswirkungen des Iran-Krieges zu konzentrieren scheint, nimmt die Quartalsberichtssaison Fahrt auf. Für die Cannabis-Unternehmen wird es möglicherweise... ► Artikel lesen |
CINCLUS PHARMA HOLDING AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +1,46 % bei einem Aktienkurs von 1,532 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CINCLUS PHARMA HOLDING AB finden Sie auf Wallstreet Online.